IP Library Granted Patent US 9,999,690
Granted Patent B2
US 9,999,690 · App. 14/534,474 · Granted Jun 19, 2018

Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,999,690
App. No.
14/534,474
Granted
Jun 19, 2018
Kind
B2
Abstract

Novel labeled compounds and metabolites thereof are disclosed, as well as pharmaceutical compositions including the compounds, and methods of using the labeled and unlabeled compounds, and specifically, 2-Amino-5-guanidino-pentanoic acid (3-{4-[3-(2-amino-5-guanidino-pentanoylamino)-propyl]-piperazin-1-yl}-propyl)-amide and metabolites thereof, for imaging, detecting and assessing disorders and diseases, such as arthritis and, more specifically, osteoarthritis by tracking proteoglycan and glycosaminoglycan content of cartilage. Also, pharmaceutical compositions comprising labeled and/or unlabeled 1,4-Bis(3-aminopropyl)piperazine are disclosed and methods of using the same.

Claims (58)

1. A method of imaging comprising:

administering to a subject in need thereof, as an imaging agent, a therapeutically effective amount of a compound selected from the group consisting of formulae (IX)-(XII) or a pharmaceutically acceptable salt thereof:

wherein:

each Y is independently selected from hydrogen, deuterium, or tritium;

each carbon denoted with an asterisk is independently selected from 12 C, 13 C, and 14 C; and

each nitrogen denoted with an asterisk is independently selected from 14 N and 15 N; and

obtaining an image.

2. The method of claim 1 , wherein the compound or the pharmaceutically acceptable salt thereof is labeled.

3. The method of claim 1 , wherein the compound or the pharmaceutically acceptable salt thereof is unlabeled.

4. The method of claim 2 , wherein the compound of formula (IX) is administered.

5. The method of claim 2 , wherein the compound of formula (IX) or the pharmaceutically acceptable salt thereof is administered.

6. The method of claim 3 , wherein the compound of formula (IX) is administered.

7. The method of claim 3 , wherein the compound of formula (IX) or the pharmaceutically acceptable salt thereof is administered.

8. The method of claim 1 , wherein the image is obtained using magnetic resonance imaging.

9. The method of claim 8 , wherein the magnetic resonance imaging is chemical shift imaging.

10. The method of claim 1 , wherein the image is obtained using radiography.

11. The method of claim 1 , wherein the method further comprises assessing osteoarthritis by tracking proteoglycan and glycosaminoglycan content of cartilage in the image.

12. The method of claim 1 , wherein the method further comprises diagnosing a growth disorder from the image.

13. The method of claim 1 , wherein the image is a urogram.

14. The method of claim 1 , wherein the method further comprises detecting an inflamed cartilage or an inflamed joint in the image.

15. The method of claim 1 , wherein the compound localizes in a cartilage, an organ, a smooth muscle fiber, and/or a tissue.

16. The method of claim 15 , wherein the compound localizes in the cartilage and is present in a concentration of about 10 micromolar to about 100 millimolar.

17. The method of claim 1 , wherein the subject is a mammal.

18. The method of claim 1 , wherein the compound resides in a cartilage, an organ, a smooth muscle fiber, and/or a tissue for about 1 hour to about 24 hours.

19. The method of claim 1 , wherein the therapeutically effective amount is about 0.001 mg/kg to about 1 g/kg of body weight per day, and

wherein the compound is administered intravenously, intra-articularly or orally.

20. A labeled compound of formula (IX) or a pharmaceutically acceptable salt thereof:

wherein:

each Y is independently selected from hydrogen, deuterium, or tritium;

each carbon denoted with an asterisk is independently selected from 12 C, 13 C, and 14 C; and

each nitrogen denoted with an asterisk is independently selected from 14 N and 15 N, and

wherein the compound includes at least one of 13 C, 14 C, 15 N, deuterium, and tritium.

21. The method of claim 4 , wherein the image is obtained using magnetic resonance imaging, and

wherein the image includes an image of a cartilage.

22. The method of claim 6 , wherein the image is obtained using magnetic resonance imaging, and

wherein the image includes an image of a cartilage.

23. A method of imaging comprising:

providing to a cartilage, an organ, a smooth muscle fiber, and/or a tissue of a subject, as an imaging agent, a compound selected from the group consisting of formulae (IX)-(XII) or a pharmaceutically acceptable salt thereof:

wherein:

each Y is independently selected from hydrogen, deuterium, or tritium;

each carbon denoted with an asterisk is independently selected from 12 C, 13 C, and 14 C; and

each nitrogen denoted with an asterisk is independently selected from 14 N and 15 N; and

obtaining an image of the cartilage, the organ, the smooth muscle fiber, and/or the tissue.

24. The method of claim 23 , wherein the compound or the pharmaceutically acceptable salt thereof is labeled.

25. The method of claim 23 , wherein the compound or the pharmaceutically acceptable salt thereof is unlabeled.

26. The method of claim 24 , wherein the imaging agent is the compound of formula (IX).

27. The method of claim 26 , wherein the image is obtained using magnetic resonance imaging.

28. The method of claim 27 , wherein the image of the cartilage is obtained.

29. The method of claim 25 , wherein the imaging agent is the compound of formula (IX).

30. The method of claim 29 , wherein the image is obtained using magnetic resonance imaging.

31. The method of claim 30 , wherein the image of the cartilage is obtained.

32. The method of claim 24 , wherein the imaging agent is the compound of formula (IX) or the pharmaceutically acceptable salt thereof.

33. The method of claim 25 , wherein the imaging agent is the compound of formula (IX) or the pharmaceutically acceptable salt thereof.

34. The method of claim 1 , wherein the subject is a human.

35. The method of claim 23 , wherein the subject is a human.

36. The method of claim 26 , wherein the subject is a human.

37. The method of claim 29 , wherein the subject is a human.

38. The compound of claim 20 , comprising at least one of 13 C, 14 C, and 15 N.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2026
From: CIRAPARANTAG HOLDINGS SARL
To: PINWHEEL THERAPEUTICS INC.
Reel/Frame 074599/0667 →
REORGANIZATION AND NAME CHANGE Recorded Nov 26, 2025
From: CIPAPARANTAG HOLDINGS GMBH
To: CIRAPARANTAG HOLDINGS SARL
Reel/Frame 073715/0571 →
IP TRANSFER AGREEMENT Recorded Oct 11, 2024
From: COVIS PHARMA GMBH
To: COVIS PHARMACEUTICALS HOLDINGS GMBH
Reel/Frame 069163/0488 →
CHANGE OF NAME Recorded Oct 11, 2024
From: COVIS PHARMACEUTICALS HOLDINGS GMBH
To: CIRAPARANTAG HOLDINGS GMBH
Reel/Frame 069168/0495 →
RELEASE OF SECURITY INTEREST Recorded Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA GMBH
Reel/Frame 059043/0226 →
SECURITY INTEREST Recorded Feb 22, 2021
From: COVIS PHARMA GMBH
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 055354/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2021
From: PEROSPHERE PHARMACEUTICALS, INC.
To: COVIS PHARMA GMBH
Reel/Frame 055241/0663 →
CHANGE OF NAME Recorded Nov 14, 2017
From: PEROSPHERE INC.
To: PEROSPHERE PHARMACEUTICALS INC.
Reel/Frame 044444/0153 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2014
From: LAULICHT, BRYAN E.; BAKHRU, SASHA H.; COSTIN, JAMES; STEINER, SOLOMON S.
To: PEROSPHERE INC.
Reel/Frame 034535/0832 →